INTRODUCTION {#sec1-1}
============

Bisphosphonates (BPs) are stable analogs of pyrophosphate, which are naturally occurring modulators of bone metabolism and have been synthesized and used since the 19^th^ century, but their *in-vitro* ability to inhibit the precipitation of calcium phosphate was applied clinically in 1960s. Oral BPs are poorly absorbed by the gastrointestinal tract about 10% and excreted largely unchanged by the kidneys, but if given intravenously nitrogen containing bisphosphonates (N-BPs) about 50% of the drugs goes to the bone.\[[@ref1][@ref2]\] BPs are commonly used to treat certain resorptive bone diseases such as osteoporosis, Paget\'s disease and hypercalcemia associated with certain malignancies such as multiple myeloma and bone metastasis from the breast or prostate.\[[@ref3][@ref4]\] Their principal action is to inhibit resorption of bone by inhibiting osteoclast activity and its life-span that leads to modulation of the osteoclast--osteoblast inter relation, which results in an increase in the mineral density of bone and a reduction in serum calcium;\[[@ref1]\] although, other actions such as inhibition of angiogenesis\[[@ref5]\] and anti-human endothelial cell proliferation and to modulate endothelial cell adhesion and migration have also been reported.\[[@ref6]\] BPs has unique pharmacokinetic properties like long retention time in bone; it is possible that beneficial effects on fracture risk may persist for some time after treatment is stopped.\[[@ref7]\] BPs has a high affinity for exposed hydroxyapatite within bone mineral and bone is metabolically inactive. As the process of metabolic bone resorption progresses, previously bound BPs is released and exerts their clinical effect.\[[@ref1]\] However, according to previous literature, all three above mentioned pharmacological action produced by N-BPs becomes more aggressive in the presence of other risk factors (drug related, local, demographic/systemic, genetic and preventive)\[[@ref4][@ref8]\] that finally leads to a rare, but serious clinical condition called N-bisphosphonate-related osteonecrosis of the jaw (BRONJ) that was first described by Marx in 2003.\[[@ref9]\]

ETIOPATHOGENESIS OF BRONJ {#sec1-2}
=========================

Chemical structure of BP \[[Figure 1](#F1){ref-type="fig"}\] has two important entity P-C-P back bone and R~2~ side chain that shows a strong affinity for bone mineral and provides potent inhibition of bone turn over both *in-vivo* and *in-vitro* and therapeutic potency of the BPs respectively. Chemically BPs had two sub-divisions, which have a different mechanism of action on osteoclasts based on the presence or absence of a nitrogen side chain on the pyrophosphate group (R~2~ side chain). N-BPs had poorly absorbed by gastrointestinal tract as compare to non-N-BPs, owing to this region N-BPs are commonly prepared for IV administration.\[[@ref1][@ref4][@ref9]\]

![Chemical structure of bisphosphonate](DRJ-11-147-g001){#F1}

Bone remodeling is a physiologically coordinated process involving bone formation by osteoblasts and bone resorption by osteoclasts. Imbalance between these two entities may lead to skeletal abnormalities characterized by increases or decreases in bone density.\[[@ref10]\] In contrast to other skeleton, jaw bones (alveolar process and periodontium) have relatively high vascularity, bone turn over and remodeling because of continuous mechanical stress.\[[@ref3]\] Such bone repair and remodeling is greatly enhances by infection and/or trauma.\[[@ref11]\] Non-N-BPs (Tiludronate, Clodronate and Etidronate) is taken up by the osteoclasts and antagonized the cellular energy pathways due to intracellular liberation of methylene that contains toxic analogs of adenosine triphosphate (ATP), which probably inhibit ATP-utilizing enzymes and induce osteoclast apoptosis, whereas N-BPs (Zoledronate, Pamidronate, Alendronateetc.,) has a more complex pathway of action where they inhibit the Mevalonate pathway by inhibition of farnesyl-pyrophosphate synthetase leading to prenylation of small GTPase signaling proteins that are essential for osteoclast activity and survival.\[[@ref3][@ref6]\] Thus, there is no osteoclastic resorption of mineral matrix and the resultant release of bone morphogenic protein and insulin-like growth to induced stem cell production of osteoblasts, the osteon becomes a-cellular and necrotic. There is sequential involution of blood vessels leaving the bone avascular. Therefore, any mechanism that leads to the breakdown of the over laying mucosa will expose the necrotic bone, which fails to heal.\[[@ref6]\] According to previous literature, Zoledronate has also been shown to inhibit human endothelial cell to proliferate and to modulate endothelial cell adhesion and migration.\[[@ref1][@ref2][@ref3][@ref12]\] Therefore, a possible association was seen between BPs and two rare but serious conditions, namely atypical femoral fracture and osteonecrosis of the jaw (ONJ)\[[@ref7]\] with an incidence of 0.8-12%\[[@ref4][@ref8]\] in IV BPs and 0.01-0.04%\[[@ref4]\] in oral BPs administration. Although the exact Pathophysiology of BPs induced ONJ has not be completely illuminated, but according to previous literature, N-BPs are potent inhibitors of osteoclastic activity, angiogenesis, human endothelial cell to proliferate and to modulate endothelial cell adhesion and migration.\[[@ref1][@ref8][@ref13][@ref14]\] Thus, the net result is that the jaw bone is unable to meet the peak demand for bone repair and remodeling that may finally lead to BRONJ.

Diagnosis, staging and clinical presentation of BRONJ {#sec2-1}
-----------------------------------------------------

Exact diagnosis criteria to distinguish BRONJ from other delayed healing conditions (alveolar osteitis, osteoradionecrosis, osteomyelitis etc.,) are not known yet today, but according to previous literature patients may be considered to have BRONJ if all of the following four characteristics are present: (1) Current or previous treatment with a BPs, (2) Exposed or necrotic bone in the maxillofacial region that has persisted for more than 8 weeks, (3) No history of radiation therapy to the jaws and (4) No evidence of cancer at the site. Lesions in patients who have not fulfilled above four characteristics should be excluded from the diagnosis of BRONJ.\[[@ref1][@ref4][@ref8][@ref15][@ref16][@ref17]\]

Radiographic findings of BRONJ are not specific and are found in other conditions such as osteomyelitis, osteoradionecrosis and metastatic bone lesions. According to previous literature most common imaging finding in ONJs is osseous sclerosis. This can vary from subtle thickening of the lamina dura and alveolar crest to attenuated osteopetrosis like sclerosis. Other findings such as Osteolysis, soft-tissue swelling, periosteal new bone formation, periapical lucencies, oroantral fistula and sequestra, which are likely to correspond with the presence of infection.\[[@ref18][@ref19]\] Its imaging differential diagnosis includes chronic sclerosing osteomyelitis, osteoradionecrosis, bone metastasis and Paget\'s disease. If osteonecrosis is suspected, different imaging techniques may be performed to confirm the diagnosis and extent of the lesions.\[[@ref17]\]

Periapical radiograph and *cone-beam computed tomography* (CBCT) reveals generalized thickening of the cortical plate and laminadura, mixed sclerotic and lytic bone destruction involving alveolar bone and basal bone, sequestrum, encroachment on the mandibular canal and maxillary antrum and pathological fracture while thickening of the cortical plate in the affected region was the only radiological findings of CBCT.\[[@ref20]\]Computed tomography images reveals sclerotic changes, osteolytic changes, periosteal bone proliferation, sequestration and inferior alveolar canal involvement while contrast enhanced magnetic resonance images reveals intensity changes of the cortical and sub cortical bone structures, contrast enhancement in necrotic bone area, soft-tissue involvement and cervical lymphadenopathy.\[[@ref9]\]99Tcm *myocardial perfusion defect* reveals detection of local bone remodeling activity/high bone turn over sites, but the presence of increased uptake was conformed through the *single-photon emission computed tomography* because they provide a high degree of accuracy.\[[@ref17]\]

In past 10 year, some important serological, histopathological and immunohistochemistry findings are obtained that may suggest the appearance of BRONJ in that patient. According to recent literature, angiogenesis suppression may play a significant role in development of BRONJ. On the basis of this evidence, Vincenzi *et al*.\[[@ref5]\] evaluated the role of *vascular endothelial growth factor* (VEGF) as a predictive marker of BRONJ and found decreased VEGF circulating levels at day 7 and 21 after the 1^st^ administration of N-BPs; thus, authors concluded that the anti-angiogenic properties of N-BPs are directly linked to BRONJ pathogenesis and serum VEGF levels could represent an effective early predictive marker. Similarly, morning fasting serum C-terminal telopertide (CTX) value is less than 100pg/ml in those patients who received/receiving N-BPs representing high risk of BRONJ development,\[[@ref9][@ref21][@ref22]\] but invasive dental procedure is only indicated if CTX value is greater than 150pg/ml to achieve, uncomplicated healing.\[[@ref19][@ref21][@ref23]\] Tissue biopsy should be performed only if metastatic diseases is suspected. Microscopic evaluation of hard tissues reveals necrotic bone spicules with bacterial colonization and inter aspersed acute and chronic inflammatory cells while soft-tissue evaluation shows proliferating stratified squamous epithelium with arcading rete pegs and neutrophilic exocytosis and adjacent fibrous connective tissue revealed the presence of patches of plasma cells, inter aspersed neutrophils and surgical hemorrhage that was similar to osteomyelitis.\[[@ref10][@ref24]\] Immuno histo-chemistry reveals increased expression of Human β defensins (hBD)-1,-2,-3, reduced expression of transforming growth factor beta1 and increased Galectin-3 expression in cases of BRONJ.\[[@ref25][@ref26]\] Microbial cultures may provide identification of the pathogens causing secondary infections (Actinomyces and other pathogens) which is important for selection of appropriate antibiotics.

Two different staging systems are encountered during preparation of this review. 1^st^ was given by recently published position paper by *American Association of Oral and Maxillofacial Surgeons* (AAOMS) (2009) while 2^nd^ was given by Olutayo *et al*. that was listed in [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"} respectively.\[[@ref4][@ref20]\] Thus, BRONJ may remain asymptomatic for many weeks or months and may only be recognized clinically by the presence of the exposed bone in the oral cavity. These lesions are most frequently symptomatic when sites becomes secondary infected or there is a trauma to the soft-tissues through the sharp edges of the exposed bone. Typical signs and symptoms include pain, soft-tissues swelling, paresthesia, suppuration, soft-tissue ulceration, loosening of teeth and drainage that is similar to osteoradionecrosis.\[[@ref15][@ref27]\] According to Lam *et al*., common orofacial findings associated with BPs associated ONJ are poor wound healing, spontaneous or post-surgical soft-tissue breakdown leading to intra oral bone exposure, bone necrosis and osteomyelitis.\[[@ref10]\] However, in severe cases some additional orofacial finding like intense pain, extensive sequestration of bone and cutaneous draining sinus tracts.\[[@ref28][@ref29]\]

###### 

AAOMS staging for BRONJ on the basis of clinical findings
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Staging for BRONJ on the basis of clinical and radiologic findings
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Risk factors of BRONJ {#sec2-2}
---------------------

According to recent position paper by AAOMS\[[@ref4]\] and NSW Health Guideline,\[[@ref8]\] risk factors for the development of BPs associated ONJ can be grouped as drug-related, local, demographic/systematic, Genetic and preventive.

Drug related risk factors include: Potency of BPs: More potent BPs (Zoledronate \> Pamidronate \>Oral BPs) have more tendency to developed ONJ. The IV route of administration resulting greater drug exposure to the jaw than the oral route; therefore more tendencies to developed ONJ. Incidence rate of BRONJ in cancer patient is increased 2.7 - 4.2 fold if given IV BPs. Longer duration therapy of BPs may be associated with increased risk of development of ONJLocal risk factors include: Dento alveolar surgery like extraction, dental implant placement, periapical surgery, periodontal surgery etc., may associate with osseous injury. BPs therapy in association with dento alveolar surgery has 7 times more likely to develop BRONJ than patients who are not having dentoalveolar surgery. Anatomic location: BRONJ is more common in the mandible than in the maxilla with the ratio of 2:1 and more common in areas with thin mucosa overlaying bony prominences like Tori, Bony exostoses and mylohyoid ridge. Concomitant oral diseases like cancer patients exposed to IV BPs with a history of inflammatory (possibly infective) dental diseases are at a 7 fold increased risk for developing ONJ.Demographic and systemic factors:- Age: With each passing decade--there is a 9% increased risk of ONJ in multiple myeloma patients treated with IV BPs, but sex was not statically associated with ONJ. Cancer type: Multiple myeloma \>\> breast cancer \> other cancer and osteopenia/osteoporosis concurrent with cancer are more prone to developed ONJ. Concomitant risk factors: Renal dialysis, low hemoglobin, Obesity, Diabetes, Tobacco users, poor oral hygiene and chemotherapeutic agents such as Cyclophosphamide, erythropoietin and steroids are risk factors, but no increased risk associated with alcohol exposure.Genetic risk factors: Like genetic perturbations, i.e., single nucleotide polymorphisms, in the cytochrome P450-2C gene (CYP2C8) gene were associated with an increased risk for ONJ among multiple myeloma patients treated with IV BPs.Preventive factors: The AAOMS Task force on BRONJ recommended that patients undergo dental evaluations and receive necessary treatment prior to initiating IV BPs therapy to reduce the incidence of BRONJ.\[[@ref30][@ref31]\] Manipulation of IV BPs dosing may be effective in reducing skeletal related events (SREs) and minimizing BPs associated ONJ.

Management of BRONJ {#sec2-3}
-------------------

Management strategies of BRONJ is mostly palliative and empirical (to eliminate clinical symptoms such as pain, infection and minimize the progression of bone necrosis) before microbial culture report.\[[@ref21][@ref32]\] Most authors agreed that management of BRONJ started after advised morning fasting serum CTX test and begins palliative care. If the exposed bone is pain less, treatment started with 0.12% chlorhexidine mouth rinse, but if patient complaints pain and/or clinical evidence of infection, antibiotic therapy should be provided in addition to the 0.12% chlorhexidine.\[[@ref4][@ref21]\] However, invasive dental procedure is indicated only when morning CTX value is greater than 150pg/ml, to achieve, uncomplicated healing.\[[@ref18][@ref21][@ref23]\]

Many treatment modalities are discussed for correction of BRONJ like cover the exposed bone areas with tissue flaps by Marx.\[[@ref33]\] Sequential removal of sequestra (conservative approach) and extensive involvement may necessitate large area of debridement to include segmental mandibulectomy and partial maxillectomy for correction of BRONJ and was reported that most patients with limited regions of exposed bone (except those lesions that are a constant source of infection) have been successfully managed with irrigations and antibiotic therapy while surgical management have not been completely effective in eradication of the BRONJ by Ruggiero *et al*.\[[@ref28]\] Administration of pentoxifylline with α-tocopherol reduces 74% area of bony exposure and symptom control by Epstein *et al*.\[[@ref34]\] Transplantation of intra-lesional autologous bone marrow stem cell with complete response by Cella *et al*.\[[@ref35]\] Mandibular reconstruction with the fibula flap by Nocini *et al*.\[[@ref36]\] and hyperbaric oxygen therapy was beneficial for patients and the outcome is increased with cessation of BPs administration.\[[@ref37][@ref38]\] No fixed treatment protocol was adopted before recent position paper published by AAOMS,(2009) that provide new treatment strategies on the basis of staging of BRONJ:

At risk-Patients who are at risk of developing BRONJ by virtue of the fact that they have been exposed to a BPs do not require any treatment. However, these patients should be informed of the risk of developing BRONJ as well as the signs and symptoms of this diseases process.

Stage 0-Here provide symptomatic treatment and conservatively manage other local factors, such as caries and periodontal disease. Systemic management may include the use of medication for chronic pain and control of infection with antibiotics, when indicated.

Stage 1-These patients benefit from the use of antiseptic mouth washes (chlorhexidine gluconate 0.12%) and/or analgesia is proposed for patients with clinical evidence of BRONJ, but in the absence of any evidence of infection. Here, primary aim is to reduce the likelihood of further progression of BRONJ and avoid infection of exposed bone, but not any surgical intervention required. However, patient education and review of indications for continued BP therapy is also important.

Stage 2-These patients benefit from the use of oral antimicrobial rinse in combination with antibiotic therapy. In BRONJ most of the isolated microbes have been sensitive to penicillin group because its development is not infectious origin. If patient was allergic to above group then choice of drug is Quinolones, Metronidazole, Clindamycin, Doxycycline and Erythromycin. If microbial cultures show positive evidence of Actinomyces species then antibiotic regimen should be adjusted accordingly. In some refractory cases, patients may require combination antibiotic therapy, long-term antibiotic maintenance or a course of IV antibiotic therapy. Sometimes superficial debridement is indicated to relieve soft-tissue irritation.

Stage 3-These patients benefit from debridement, including resection, in combination with antibiotic therapy, which may offer long-term palliation with resolution of acute infection and pain.

Regardless of the disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone. The extraction of symptomatic teeth within exposed, necrotic bone should be considered since it is unlikely that the extraction will exacerbate the established necrotic process.

CONCLUSION {#sec1-3}
==========

BPs associated ONJ is a rare, but serious clinical condition caused by anti-osteoclastic, anti-angiogenic and anti-human endothelial cell proliferation effects of BPs, which inhibit bone turnover. They are commonly developed in those patients who are receiving either long term nitrogen containing IV BPs therapy alone or associated with invasive dental procedure. Therefore, proper dental evaluations and receiving necessary treatment prior to initiating IV BPs therapy is recommended.. Manipulation of IV BPs dosing may be effective in reducing SREs and minimizing BPs associated ONJ. CBCT and morning fasting CTX level are the useful assessment tool to predict risk and to make appropriate line of treatment. In cases of established disease management strategies is mostly palliative and empirical.
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